HQL-79

HQL-79, a potent, selective and orally active human hematopoietic prostaglandin D synthase (H-PGDS) inhibitor, highly selectively inhibits the synthesis of PGD2, and acts as an anti-allergic agent, with a Kd of 0.8 μM and an IC50 of 6 μM. Shows no obvious effect on COX-1, COX-2, m-PGES, or L-PGDS[1].

Product Specifications

CAS Number

[162641-16-9]

UNSPSC

12352005

Target

PGE synthase

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/hql-79.html

Purity

99.89

Solubility

DMSO : 2 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

N1(CCCC2=NN=NN2)CCC(OC(C3=CC=CC=C3)C4=CC=CC=C4)CC1

Molecular Formula

C22H27N5O

Molecular Weight

377.48

References & Citations

[1]Aritake K, et al. Structural and functional characterization of HQL-79, an orally selective inhibitor of human hematopoietic prostaglandin D synthase. J Biol Chem. 2006 Jun 2;281 (22) :15277-86. Epub 2006 Mar 17.